Festus Samah v. Takeda Pharmaceuticals U.S.A., Inc.

CourtDistrict Court, D. Massachusetts
DecidedJanuary 8, 2026
Docket1:25-cv-10158
StatusUnknown

This text of Festus Samah v. Takeda Pharmaceuticals U.S.A., Inc. (Festus Samah v. Takeda Pharmaceuticals U.S.A., Inc.) is published on Counsel Stack Legal Research, covering District Court, D. Massachusetts primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Festus Samah v. Takeda Pharmaceuticals U.S.A., Inc., (D. Mass. 2026).

Opinion

UNITED STATES DISTRICT COURT DISTRICT OF MASSACHUSETTS

) FESTUS SAMAH, ) ) Plaintiff, ) ) v. ) No. 1:25-cv-10158-JEK ) TAKEDA PHARMACEUTICALS ) U.S.A., INC., ) ) Defendant. ) )

MEMORANDUM AND ORDER ON DEFENDANT’S PARTIAL MOTION TO DISMISS

KOBICK, J. Plaintiff Festus Samah brings this action against his former employer, defendant Takeda Pharmaceuticals U.S.A., Inc., alleging that it violated state and federal laws by discriminating against him based on his race and sex, subjecting him to a hostile work environment, failing to properly pay him for time worked, and retaliating against him for complaining about these violations. Pending before the Court is Takeda’s partial motion to dismiss eleven of Samah’s fifteen claims. For the reasons that follow, the motion will be granted in part and denied in part. The claims of sex discrimination under Title VII and M.G.L. c. 151B will be dismissed for failure to exhaust administrative remedies. The portion of his Title VII claim asserting retaliation based on his reporting of sex-based discrimination will be dismissed for the same reason. Samah’s remaining claims survive dismissal. The Title VII and Chapter 151B claims are timely because Samah plausibly alleges that Takeda constructively discharged him. He also adequately pleads that Takeda discriminated against him on the basis of race and subjected him to a racially hostile work environment. And he sufficiently states claims of retaliation under the Fair Labor Standards Act, the Massachusetts Wage Act, and the Massachusetts Earned Sick Time Law. BACKGROUND The following facts are recounted based on the allegations in the amended complaint and

documents attached to, or sufficiently referenced in, that pleading. Thornton v. Ipsen Biopharmaceuticals, Inc., 126 F.4th 76, 81 (1st Cir. 2025). Samah was employed by Takeda as a research associate from August 2022 until July 2023. ECF 14, ¶¶ 3, 6, 13, 54. Takeda is an international biopharmaceutical company that operates two laboratories in Cambridge, Massachusetts, where Samah worked. Id. ¶¶ 5, 17. He was the only Black person on his team and believed that his coworkers and supervisor, Shylah Wyllie, treated him differently because of his race. Id. ¶¶ 12, 14, 22, 28. Samah was, for example, “assigned jobs that a researcher of lower designation would ordinarily do” and “undesirable tasks like mopping and sweeping.” Id. ¶¶ 25-26, 65. One colleague was also “particularly cruel and would continuously bully and intimidate him” because of his race. Id. ¶¶ 27-28, 65, 69. Samah reported

to Wyllie that he felt “discriminated against and bullied,” but his complaints went unaddressed. Id. ¶¶ 22, 29, 65. In February 2023, Samah requested two weeks off because “he was experiencing mental anguish” from “his colleagues’ and supervisor’s treatment” and wanted to care for his then- pregnant wife, who had recently been hospitalized. Id. ¶ 30. Right after this request, Wyllie emailed a member of the human resources team that Samah’s choice to take available sick leave gave rise to concerns about his performance. Id. ¶ 31. When he returned from the two weeks off in March 2023, Takeda placed him on a coaching plan. Id. ¶ 34. In June 2023, Samah received an $1,800 bonus, while his white colleagues received $5,000 bonuses. Id. ¶ 41. Takeda did not explain this disparity. Id. ¶ 42. Around the same time, in June 2023, Samah “also complained about not being paid for his travel time and for the time he was entitled to for weekend and holiday shifts.” Id. ¶ 43. Samah estimates that he was underpaid by at least two hours every weekend because Takeda paid him only for lab work, not his “time spent preparing the testing area, preparing the systems

to record data, [or] traveling between” laboratories. Id. ¶¶ 20-21. On June 7, 2023, Samah requested Massachusetts Paid Family and Medical Leave (“PFML”) time, to start in October 2023, in anticipation of his child’s birth. Id. ¶ 44. Takeda placed Samah on a 60-day performance improvement plan (“PIP”) less than three weeks later, on June 26, 2023. Id. ¶ 46. On July 6, 2023, Takeda offered him the option to either separate from the company or continue working under the PIP. Id. ¶¶ 48-49. Samah was told “that nothing would change”; among other things, “his co-workers and supervisors would continue to force him to complete undesirable tasks and treat him differently than his white co-workers” and “his lawful use of time off and leave would continue to be unfairly scrutinized.” Id. ¶ 51. Samah chose to separate instead of enduring these “intolerable” working conditions where, he alleges, he was

consistently treated differently and retaliated against. Id. ¶¶ 51-53. On July 17, 2023, he received a separation agreement from Takeda with an official separation date of July 19, 2023. Id. ¶ 54. Samah co-filed a charge of discrimination with the Massachusetts Commission Against Discrimination (“MCAD”) and Equal Employment Opportunity Commission (“EEOC”) on May 3, 2024. Id. ¶ 56; see ECF 18-1. He withdrew his charge with MCAD in October 2024 and received his right to sue notice from EEOC in March 2025. ECF 14, ¶ 58. He then initiated this action in January 2025 and filed an amended complaint in March 2025. ECF 1, 14. Samah asserts claims for retaliation in violation of M.G.L. c. 175M, § 9 (Count 1); Title VII of the Civil Rights Act of 1964, 42 U.S.C. § 2000e-3(a) (Count 4); the Massachusetts Fair Employment Practices Act, M.G.L. c. 151B, § 4(4) (Count 8); the Fair Labor Standards Act (“FLSA”), 29 U.S.C. § 215(a)(3) (Count 11); the Massachusetts Wage Act, M.G.L. c. 149, § 148A (Count 13), and the Massachusetts Earned Sick Time Law, M.G.L. c. 149, § 148C(h) (Count 15). ECF 14, ¶¶ 61, 64, 68, 71, 73, 75. He alleges that Takeda violated Title VII and Chapter 151B by discriminating against him on the

basis of his race (Counts 2 and 6, respectively) and sex (Counts 3 and 7, respectively). Id. ¶¶ 62- 63, 66-67. He asserts that Takeda subjected him to a hostile work environment in violation of Title VII and Chapter 151B (Counts 5 and 9, respectively). Id. ¶¶ 65, 69. And he claims that Takeda failed to pay him properly in violation of the FLSA (Count 10), the Massachusetts Wage Act (Count 12), and M.G.L. c. 151, § 1 (Count 14). Id. ¶¶ 70, 72, 74. Takeda moved to dismiss Counts 2 through 9, 11, 13, and 15. ECF 17. After Samah opposed that motion and Takeda filed its reply, the Court held a hearing and took the motion under advisement. ECF 21, 25, 28. STANDARD OF REVIEW In evaluating a motion to dismiss under Federal Rule of Civil Procedure 12(b)(6), the Court

must determine “whether, construing the well-pleaded facts of the complaint in the light most favorable to the plaintif[f], the complaint states a claim for which relief can be granted.” Cortés- Ramos v. Martin-Morales, 956 F.3d 36, 41 (1st Cir. 2020) (quotation marks omitted). The complaint must allege “a plausible entitlement to relief.” Bell Atl. Corp. v. Twombly, 550 U.S. 544, 559 (2007). “A claim has facial plausibility when the plaintiff pleads factual content that allows the court to draw the reasonable inference that the defendant is liable for the misconduct alleged.” Ashcroft v. Iqbal, 556 U.S. 662, 678 (2009). “While legal conclusions can provide the framework of a complaint, they must be supported by factual allegations.” Id. at 679.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Harris v. Forklift Systems, Inc.
510 U.S. 17 (Supreme Court, 1993)
Oncale v. Sundowner Offshore Services, Inc.
523 U.S. 75 (Supreme Court, 1998)
Pennsylvania State Police v. Suders
542 U.S. 129 (Supreme Court, 2004)
Bell Atlantic Corp. v. Twombly
550 U.S. 544 (Supreme Court, 2007)
Ashcroft v. Iqbal
556 U.S. 662 (Supreme Court, 2009)
Gorelik v. Costin, Pa-C
605 F.3d 118 (First Circuit, 2010)
LaChapelle v. Berkshire Life Insurance
142 F.3d 507 (First Circuit, 1998)
Landrau-Romero v. Banco Popular De Puerto Rico
212 F.3d 607 (First Circuit, 2000)
Blackstone Realty LLC v. Federal Deposit Insurance
244 F.3d 193 (First Circuit, 2001)
Che v. Massachusetts Bay Transportation Authority
342 F.3d 31 (First Circuit, 2003)
Lee-Crespo v. Schering-Plough Del Caribe Inc.
354 F.3d 34 (First Circuit, 2003)
Thompson v. Coca-Cola Co.
522 F.3d 168 (First Circuit, 2008)
Thornton v. United Parcel Service, Inc.
587 F.3d 27 (First Circuit, 2009)
Luis Aldahonda-Rivera v. Parke Davis & Company
882 F.2d 590 (First Circuit, 1989)
Bhatti v. Trustees of Boston University
659 F.3d 64 (First Circuit, 2011)
Rodriguez-Reyes v. Molina-Rodriguez
711 F.3d 49 (First Circuit, 2013)
Fantini v. Salem State College
557 F.3d 22 (First Circuit, 2009)

Cite This Page — Counsel Stack

Bluebook (online)
Festus Samah v. Takeda Pharmaceuticals U.S.A., Inc., Counsel Stack Legal Research, https://law.counselstack.com/opinion/festus-samah-v-takeda-pharmaceuticals-usa-inc-mad-2026.